Consolidated Statement of Stockholders' Equity (USD $)	Total	Equity Issued in Business Combination	Common stock issued @ $3.80	Common stock issued @ $3.70	Common stock issued @ $4.00	Common stock issued @ 6.23	Common stock issued @ $5.11	Common stock issued @ $2.76	Preferred stock issued at $1,000 per share	Issued To Calando Stockholders In Exchange For Calando S Shares	Common stock issued @ $4.49	Common stock issued @ $2.26	Common stock issued @ $2.12	Common stock issued @ $1.83	Common stock issued @ $5.86	Common stock issued @ $18.95	Common Stock Issued to Galloway	Preferred Stock	Preferred Stock Preferred stock issued at $1,000 per share	Common Stock	Common Stock Equity Issued in Business Combination	Common Stock Common stock issued @ $3.80	Common Stock Common stock issued @ $3.70	Common Stock Common stock issued @ $4.00	Common Stock Common stock issued @ 6.23	Common Stock Common stock issued @ $5.11	Common Stock Common stock issued @ $2.76	Common Stock Issued Under Committed Capital Agreement	Common Stock Common stock issued @ $4.49	Common Stock Common stock issued @ $2.26	Common Stock Common stock issued @ $2.12	Common Stock Common stock issued @ $1.83	Common Stock Common stock issued @ $5.86	Common Stock Common stock issued @ $18.95	Common Stock Common Stock Issued to Galloway	Additional Paid-in Capital	Additional Paid-in Capital Equity Issued in Business Combination	Additional Paid-in Capital Common stock issued @ $3.80	Additional Paid-in Capital Common stock issued @ $3.70	Additional Paid-in Capital Common stock issued @ $4.00	Additional Paid-in Capital Common stock issued @ 6.23	Additional Paid-in Capital Common stock issued @ $5.11	Additional Paid-in Capital Common stock issued @ $2.76	Additional Paid-in Capital Issued Under Committed Capital Agreement	Additional Paid-in Capital Preferred stock issued at $1,000 per share	Additional Paid-in Capital Common stock issued @ $4.49	Additional Paid-in Capital Common stock issued @ $2.26	Additional Paid-in Capital Common stock issued @ $2.12	Additional Paid-in Capital Common stock issued @ $1.83	Additional Paid-in Capital Common stock issued @ $5.86	Additional Paid-in Capital Common stock issued @ $18.95	Additional Paid-in Capital Common Stock Issued to Galloway	Subscriptions Receivable	Subscriptions Receivable Common stock issued @ $3.80	Subscriptions Receivable Common stock issued @ $2.76	Accumulated Deficit during Development Stage	Noncontrolling Interest	Noncontrolling Interest Issued To Calando Stockholders In Exchange For Calando S Shares
Beginning Balance Amount at Sep. 30, 2011	$ 12,564,167																			$ 86,422																$ 127,476,435																	$ (900,000)			$ (113,871,752)	$ (226,938)
Beginning Balance Shares at Sep. 30, 2011																				8,642,286
Exercise of warrants, Amount	50,406																			16																50,390
Exercise of warrants																				15,511
Stock options exercised, Amount	23,833									8,000										45																23,788																						8,000
Stock options exercised																				4,583
Stock-based compensation	1,241,404																																			1,241,404
Stock issuances		6,147,830	425,000	2,247,750	400,000	500,001	500,001	5,796,240	1,015,000										1		9,332	1,382	6,750	1,000	83	98	2,261	689									6,138,498	523,618	2,241,000	399,000	499,918	499,903	5,809,979	(689)	1,014,999									(100,000)	(16,000)
Stock issuances, Shares																			1,015		1,217,159	138,158	675,000	100,000	83,211	97,831	2,260,869	68,926
Fractional shares redeemed in reverse stock split																				(131)
Preferred stock converted to common stock, Amount																		(1)		276																(275)
Preferred stock converted to common stock, Shares																		(1,015)		275,782
Net loss	(22,110,723)																																																							(21,125,928)	(984,795)
Ending Balance Amount at Sep. 30, 2012	8,808,909																			108,354																145,917,968																	(1,016,000)			(134,997,680)	(1,203,733)
Ending Balance Shares at Sep. 30, 2012																				13,579,185
Exercise of warrants, Amount	2,054,599																			1,183																2,053,416
Exercise of warrants																				1,182,451
Stock options exercised, Amount	2,579																			1																2,578
Stock options exercised	675																			675
Stock-based compensation	1,536,271																																			1,536,271
Subscription payment	16,000																																																				16,000
Subscription reversal, Amount																				(2,674)																(997,326)																	1,000,000
Subscription reversal																				(267,444)
Stock issuances									9,900,000		986,049	3,816,468	3,256,859	25,459,499					10										240	1,825	1,667	14,263													9,899,990	985,809	3,814,643	3,255,192	25,445,236
Stock issuances, Shares																			9,900										239,894	1,825,079	1,667,051	14,262,553
Net loss	(31,703,433)																																																							(31,143,289)	(560,144)
Establish and settlements related to derivative liability	1,600,989																																			1,600,989
Ending Balance Amount at Sep. 30, 2013	25,734,789																	10		124,859																193,514,766																				(166,140,969)	(1,763,877)
Ending Balance Shares at Sep. 30, 2013																		9,900		32,489,444
Exercise of warrants, Amount	10,148,044																			2,911																10,145,133
Exercise of warrants																				2,911,919
Stock options exercised, Amount	2,730,000																			455																2,729,545
Stock options exercised	454,863																			454,863
Stock-based compensation	5,696,173																																			5,696,173
Stock issuances									46,000,000						14,060,112	112,581,559	500,000		46														3,072	6,325	132										45,999,954					14,057,040	112,575,234	499,868
Stock issuances, Shares																			46,000														3,071,672	6,325,000	131,579
Preferred stock converted to common stock, Amount																		(38)		9,272																(9,234)
Preferred stock converted to common stock, Shares																		(37,600)		9,272,459
Net loss	(58,725,412)																																																							(58,630,190)	(95,222)
Establish and settlements related to derivative liability	5,956,079																																			5,956,079
Deconsolidation of Calando Pharmaceuticals, Inc.	1,303,911																																																								1,303,911
Ending Balance Amount at Sep. 30, 2014	$ 165,985,255																	$ 18		$ 147,026																$ 391,164,558																				$ (224,771,159)	$ (555,188)
Ending Balance Shares at Sep. 30, 2014																		18,300		54,656,936